Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Chiara Corti, M.D.

Concepts (121)

Back to Profile
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Immunoconjugates720239541.940 Why?
Breast Neoplasms202024210121.420 Why?
Thymus Neoplasms420222741.170 Why?
Thymoma320221881.090 Why?
Neoplasms142024221700.820 Why?
Breast Neoplasms, Male220202190.770 Why?
Artificial Intelligence3202325780.670 Why?
DNA Mismatch Repair220204280.660 Why?
Antineoplastic Agents62023136390.620 Why?
Cancer Vaccines2202110510.570 Why?
Gastrointestinal Stromal Tumors120226170.530 Why?
Microsatellite Instability120197160.500 Why?
Neoadjuvant Therapy2202428270.450 Why?
Tumor Microenvironment3202238770.410 Why?
Receptor, erbB-26202425570.340 Why?
Neoplasms, Glandular and Epithelial220224870.300 Why?
Antineoplastic Combined Chemotherapy Protocols62023117420.280 Why?
Brain Neoplasms3202390310.270 Why?
Melanoma2202257090.270 Why?
Humans4720247615040.230 Why?
PTEN Phosphohydrolase2202011150.230 Why?
Immunotherapy7202446520.220 Why?
Molecular Targeted Therapy3202428110.210 Why?
Compassionate Use Trials12022500.200 Why?
Ifosfamide120232320.200 Why?
Polymyositis12022750.200 Why?
Chemotherapy, Adjuvant2202135140.200 Why?
Mutation32022300520.190 Why?
Vaccines, Virus-Like Particle12021450.180 Why?
Vaccines, Subunit120211610.180 Why?
Vaccines, Inactivated120211790.180 Why?
Triazines120223110.180 Why?
Prognosis62024296250.170 Why?
Antibodies, Viral2202131560.170 Why?
Vaccines, Attenuated120213150.170 Why?
Oxazoles120211990.170 Why?
Female2320243926440.170 Why?
Apocrine Glands12019320.170 Why?
Pyrroles2202211250.160 Why?
Proto-Oncogene Proteins c-kit120227270.150 Why?
Vaccines, Synthetic120216160.150 Why?
Receptors, Estrogen2202322080.150 Why?
Lung Neoplasms42023133800.150 Why?
Carcinoma, Lobular120214810.140 Why?
Aromatase Inhibitors120205130.140 Why?
Genetic Counseling120206270.140 Why?
Exons1202223910.130 Why?
Tamoxifen120209650.130 Why?
Gonadotropin-Releasing Hormone1202011480.120 Why?
Quinazolines1202113710.120 Why?
Carcinoma, Intraductal, Noninfiltrating120219260.120 Why?
Carcinoma, Ductal, Breast1202110850.120 Why?
Antigens, Neoplasm1202219930.110 Why?
Drug Approval120218140.110 Why?
Carcinoma, Non-Small-Cell Lung2202353150.110 Why?
Membrane Transport Proteins1201910350.110 Why?
Antineoplastic Agents, Hormonal1202015200.100 Why?
Immunotherapy, Adoptive1202214690.100 Why?
Radiosurgery1202113420.100 Why?
High-Throughput Screening Assays120179340.100 Why?
Pyrazoles1202220090.100 Why?
Prospective Studies52023544250.100 Why?
Proto-Oncogene Proteins B-raf1202120570.090 Why?
Autoimmune Diseases1202222440.080 Why?
Combined Modality Therapy1202185290.080 Why?
Vaccination1202133840.080 Why?
Randomized Controlled Trials as Topic52024102090.080 Why?
Pyridines1202128750.080 Why?
Protein Kinase Inhibitors2202356710.080 Why?
Genetic Testing1202035370.070 Why?
Epithelial Cells1201936730.070 Why?
Neoplasm Proteins1201936170.070 Why?
Clinical Trials as Topic1202180020.060 Why?
Immunohistochemistry12019110760.060 Why?
Reproducibility of Results12022200980.060 Why?
Gene Expression Regulation, Neoplastic1202085470.060 Why?
Incidence12021213530.050 Why?
Treatment Outcome42022646800.050 Why?
Mesna12023620.050 Why?
Early Detection of Cancer1201732010.050 Why?
Immunologic Factors2202215890.050 Why?
Algorithms12022140310.050 Why?
Bystander Effect12022900.050 Why?
Platinum120222200.050 Why?
Technology120212920.040 Why?
Workflow120238510.040 Why?
Receptors, Progesterone1202311290.040 Why?
Disease-Free Survival2202068140.040 Why?
Retrospective Studies32022806360.040 Why?
Patient Care120236220.040 Why?
Cardiovascular Diseases12023155000.040 Why?
Clinical Trials, Phase III as Topic120218570.040 Why?
Quality of Life32023133670.040 Why?
Hyperplasia1201911520.030 Why?
Axilla120186240.030 Why?
Neoplasm Recurrence, Local2202392800.030 Why?
MAP Kinase Signaling System1202114860.030 Why?
Indoles1202218330.030 Why?
Gene Amplification1201710890.030 Why?
Breast1202119670.030 Why?
Animals220211684590.030 Why?
Angiogenesis Inhibitors1202220470.030 Why?
Lymph Node Excision1201812710.030 Why?
In Situ Hybridization, Fluorescence1201725100.020 Why?
HeLa Cells1201730930.020 Why?
Recurrence1202384650.020 Why?
Medical Oncology1202323210.020 Why?
Neoplasm Invasiveness1201835950.020 Why?
Neoplasm Staging12024111210.020 Why?
Male320213608040.020 Why?
Follow-Up Studies22019391060.020 Why?
Lymph Nodes1201834660.020 Why?
Survival Rate12020127250.020 Why?
Case-Control Studies12023221760.020 Why?
Aged, 80 and over22020589760.010 Why?
Aged320201692890.010 Why?
Skin Neoplasms1202158210.010 Why?
Middle Aged320202208950.010 Why?
Adult320202211770.010 Why?
Brain12023271120.010 Why?
Adolescent12022883190.010 Why?
Corti's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (121)
Explore
_
Co-Authors (14)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2024 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.